Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.

Cancer research·2026
Same author

Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition.

Molecular therapy. Oncology·2026
Same author

A Vascularized Microphysiological System Reproducing Endochondral Ossification in Vitro to Study Ewing Sarcoma Proliferation and Migration.

Advanced functional materials·2026
Same author

Potential biomarkers of Ewing sarcoma identified through a Europe-wide analysis of prospectively collected samples.

Scientific reports·2026
Same author

Beyond the mouse: 3R-guided alternative animal models transforming cancer research.

Molecular cancer·2026
Same author

Differential immune infiltrates in histomorphologic Wilms tumor regions identify prognostic macrophages.

Molecular therapy. Oncology·2026

Related Experiment Video

Updated: Feb 8, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.3K

Ewing sarcoma.

Thomas G P Grünewald1,2,3,4, Florencia Cidre-Aranaz5,6,7,8, Didier Surdez9

  • 1Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany. thomas.gruenewald@med.uni-muenchen.de.

Nature Reviews. Disease Primers
|July 7, 2018
PubMed
Summary

Ewing sarcoma, a rare childhood cancer, is driven by the EWSR1-FLI1 fusion gene. Understanding its molecular mechanisms offers hope for better treatments and improved survival rates.

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K

Related Experiment Videos

Last Updated: Feb 8, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.3K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K

Area of Science:

  • Pediatric Oncology
  • Molecular Oncology
  • Cancer Genetics

Background:

  • Ewing sarcoma is a prevalent and aggressive bone and soft tissue cancer in children and adolescents.
  • Current treatments lead to significant adverse effects, impacting survivors' quality of life.
  • Survival rates are poor for metastatic disease, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To elucidate the molecular underpinnings of Ewing sarcoma.
  • To identify potential targets for improved early detection and treatment.
  • To explore strategies for reducing treatment toxicity and enhancing patient outcomes.

Main Methods:

  • Histological analysis of small round cells expressing CD99.
  • Genetic analysis of chromosomal translocations, focusing on EWSR1-FLI1 fusion.
  • Epigenomic profiling to identify altered gene regulatory elements and de novo enhancers.

Main Results:

  • Ewing sarcoma is characterized by the EWSR1-FLI1 chimeric transcription factor in 85% of cases.
  • EWSR1-FLI1 extensively rewires the transcriptome and epigenome, creating a unique cancer signature.
  • Additional mutations in STAG2, TP53, and CDKN2A are infrequent at diagnosis.

Conclusions:

  • Molecular insights into Ewing sarcoma are crucial for advancing early detection and disease monitoring.
  • Targeting EWSR1-FLI1 and its associated molecular pathways holds promise for novel therapies.
  • Further research may lead to reduced treatment toxicity, improved survival, and better quality of life for patients.